WHAT’S NEW: Boston Scientific Corp. offered $25 billion in cash and stock Monday for Guidant Corp. just three weeks after Guidant accepted a renegotiated price of $21.5 billion from Johnson & Johnson.

GUIDANT’S REACTION: The Indianapolis-based medical device maker said in a terse statement its board would consider the Boston Scientific offer and that it would not comment further for now.

WHAT’S NEXT: The Guidant-J&J agreement likely includes a provision giving J&J a set time period to match any offer that Guidant’s board deems better than J&J’s.